repotrectinib Augtyro
Selected indexed studies
- Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. (N Engl J Med, 2024) [PMID:38197815]
- Repotrectinib: First Approval. (Drugs, 2024) [PMID:38279972]
- Repotrectinib. (, 2006) [PMID:38163333]
_Worker-drafted node — pending editorial review._
Connections
repotrectinib Augtyro is a side effect of
Sources
- Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. (2024) pubmed
- Repotrectinib. (2006) pubmed
- Repotrectinib. (2012) pubmed
- Repotrectinib: First Approval. (2024) pubmed
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. (2018) pubmed
- Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer. (2024) pubmed
- Repotrectinib (Augtyro) for non-small cell lung cancer. (2024) pubmed
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update. (2024) pubmed
- CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. (2024) pubmed
- Advances and future directions in ROS1 fusion-positive lung cancer. (2024) pubmed